Winway Health Desk
Physicians still miserable: Seven solutions to address burnout
“When all of the scheduled patients show up it makes work unbearable. Taking a break to use the bathroom or eat is then a...
IT will be key to precision medicine’s success in 2020
Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic...
Final Modules Set For Crisis Stabilization Unit
Final modules for a new two-story crisis stabilization unit (CSU) in Aventura, Fla., were lofted into place last week. The new CSU will serve...
Reeves County Hospital Replacement Facility Breaks Ground
Reeves County Hospital District staff members, Robins & Morton, and community members gathered to celebrate the groundbreaking of the new Reeves County Hospital replacement...
Spiezle Architectural Group Acquires City Invincible Architecture
Spiezle Architectural Group, Inc., has acquired City Invincible Architecture, Interiors and Urban Design of Camden, N.J. This strategic acquisition is expected to bolster Spiezle’s...
Builders Complete Inpatient Treatment Center In Missouri
Wiegmann Associates has completed HVAC work on the new two-story, 53,000-square-foot Harris House Intensive Inpatient Treatment Center in St. Charles, Mo. Wiegmann served as...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug...
PHOTO TOUR: Platte Valley Medical Center
SCL Health completed a build out of 17,000 square feet of existing shell space to create a 28-bed medical/surgery unit on the third floor...
Oklahoma judge chops $107M from Johnson & Johnson’s opioid verdict
After losing the nation’s first major opioid trial in Oklahoma this summer, Johnson & Johnson lawyers sought to reduce the company's liability. Now, a judge has chopped...
Pfizer scores FDA nod for biosim to AbbVie’s Humira, but it’ll...
AbbVie is preparing for the costly U.S. loss of Humira exclusivity in 2023, and now there’s another pharma giant that has scored a biosimilar...
